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Qualidade de vida de pacientes portadores de doença inflamatória intestinal
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ABSTRACT
Objectives: To assess the quality of  life (QV) in patients with inflammatory bowel disease (DII), and relate it to demographic data and
morbidity. Methods: Cross-sectional study with 103 patients with DII, registered in the high cost pharmacy of  Cuiabá - Mato Grosso, who
responded to the Standard Medical Record, the general QV questionnaire SF-36 and the specific IBDQ. Results: Among 103 patients with
DII, 62 had ulcerative colitis and 41 had Crohn’s disease; 62% were women; 69.9% were married; 48.5% were of  mixed race; 49.5% were
smokers; 37.9% required surgery; and, 40.8% had active disease. We observed significant changes in QV in men, smokers and those with
active disease. Conclusion: DII affect QV in several respects. Measures for maintenance of  QV, psychological, social and education support
should be considered for patients with DII.
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RESUMO
Objetivos: Avaliar a qualidade de vida (QV) de portadores de doenças inflamatórias intestinais (DII) e relacionar dados sociodemográficos
e mórbidos à QV. Métodos: Estudo transversal, realizado com 103 portadores de DII, cadastrados na farmácia de alto custo de Cuiabá -
Mato Grosso que responderam ao Prontuário-Padrão, ao questionário de QV geral SF36 e ao específico IBDQ. Resultados: Dentre os 103
pacientes com DII, 62 tinham retocolite ulcerativa idiopática e 41 doença de Crohn; 62% eram mulheres; 69,9%, casados; 48,5%, pardos;
49,5%, fumantes, 37,9% necessitaram de cirurgia e 40,8% apresentavam doença em atividade. Foi observada alteração significativa da QV
em homens, fumantes e entre aqueles com doença em atividade. Conclusão: DII afetam a QV em diversos aspectos. Medidas para
manutenção da QV, suporte psicológico, social e educacional devem ser considerados para portadores de DII.
Descritores: Doença inflamatória intestinal; Doença de Crohn; Retocolite ulcerativa; Colite; Qualidade de vida
RESUMEN
Objetivos: Evaluar la calidad de vida (CV) de portadores de enfermedades inflamatorias intestinales (EII) y relacionar datos sociodemográficos
y mórbidos a la CV. Métodos: Se trata de un estudio transversal, realizado con 103 portadores de EII, registrados en la farmacia de alto costo
de Cuiabá - Mato Grosso que respondieron a la  Historia Clínica-Patrón, al cuestionario de CV general SF36 y al específico IBDQ. Resultados:
De los 103 pacientes con EII, 62 tenían rectocolitis ulcerosa idiopática y 41 enfermedad de Crohn; 62% eran mujeres; 69,9%, casados; 48,5%,
pardos; 49,5%, fumadores, 37,9% necesitaron de cirugía y 40,8% presentaban la enfermedad en actividad. Fue observada una alteración
significativa de la CV en hombres, fumadores y en aquellos con la enfermedad en actividad. Conclusión: Las EII afectan la CV en diversos
aspectos. Para la manutención de la CV, deben ser considerados el soporte psicológico, social y educacional de los portadores de EII.
Descriptores: Enfermedad inflamatoria intestinal; Enfermedad de Crohn; Colite ulcerosa; Colite; Calidad de vida
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INTRODUCTION
Crohn’s Disease (CD) and idiopathic ulcerative colitis
(IUC) are the most commonly found forms of
inflammatory bowel disease (IBD) and is characterized
by chronic inflammation of the bowel with an unknown
etiology.  It has incidence worldwide and represents a
serious health problem, it affects young people, the
course presents frequent recurrence, and there are highly
severe clinical forms(1-2). This disease leads to important
outcomes in patients’ quality of life (QL)(3). Several
epidemiological studies have demonstrated a growing
incidence of CD and IUC in the last decades(4-5).  IBD
affects people from different socioeconomic classes, age,
gender, and nationality. In the United States (USA), about
1.4 million people present one of  the forms of  IBD(6);
in Europe 2.2 millions(7) and in Canada, about 150
thousand people present it(8). USA, England, Italy,
Scandinavia and the countries of the North Region of
Europe are classified as areas with high rate of  IBD,
South of Europe, South Africa, Australia, and New
Zealand are regions with intermediate incidence and Asia
and South America are considered as low incidence
regions(9). For many years, the considered presence of
IDB was restricted to North America and Europe. There
was an increase in its incidence in South America as
physicians have become more able to diagnose the
disease. The majority of  information on IBD is available
in First World countries where the disease prevalence is
higher. In Brazil, where the official prevalence is still low,
there is little information in the literature. A significant
increase of the incidence of IBD has been recorded in
our environment in the South and Southeast region(9).
Although it is considered a region with low
prevalence, the reality in Brazil can be different because
there are no effective public health records on IDB. This
disease is not classified as mandatory report and the notes
in patients’ charts and in health care services files are
poor. Most patients that look for health care with
complaints of diarrhea and abdominal pain are
diagnosed as diarrhea with a bacterial or parasitic
etiology; however, a more detailed investigation of  these
cases could lead to the diagnoses of  IDB, which is based
on the clinical and laboratory picture, and in the
combination of patients’ endoscopic, histological and
image data.
Clinical treatment of IDB is complex because of
the enigmatic pathogenesis, the limited knowledge of
the underlying immunological and inflammatory events,
and the lack of a standard pattern to measure the disease
activity. Up to now, the therapeutic intervention focuses,
above all, on fighting the consequences generated by the
amplification of the immune and inflammatory cascades
and the resulting systemic repercussion(10). The therapy
measures depend on the form, extension and severity
of the disease.
The quality of  life is determined by the extension in
which ambitions and hopes correspond to the personal
experience; by individuals’ perceptions on their position
in life, taking into account the context of the culture and
the systems of values in which people live regarding
their objectives, expectations, standards and concepts,
assessing their current state compared to their ideals, as
well as by what people consider as important factors
of their lives(11).
Measuring the QL is an important parameter to
assess the impact of chronic diseases, since even though
physiological changes provide important information
to the GP, they can present different effects in patients
and family members because they influence the functional
capacity and the well being which are essential aspects
to sick people(12). In a recent bibliographical survey
carried out in a broad manner, we have not found data
on the QL of patients with IDB in the State of Mato
Grosso. Thus, we consider that a study on the
identification of the sociodemographic, economic, and
health characteristics and the assessment of QL of
patients with IDB can provide important information
on the profile of patients and can help create the
guidelines for the most adequate treatment.
METHODS
The study was carried out after the approval of the
research project by the Research Ethics Committee of
the University Hospital Júlio Muller and by the Research
Ethics Committee at Universidade Federal de São Paulo,
with patients with IBD registered in the program for
dispensing exceptional drugs of the Health Secretariat
of  the State of  Mato Grosso, from October 2006 to
November 2007 after they were assessed by an auditing
physician. These patients came from the public and
private health care network and there were citizens from
different cities of the State.
The program for dispensing exceptional drugs
provides high cost drugs for free, including those used
in IBD. It was implemented by the Ministry of  Health
through the Ordinance # 1.318/02. Patients are included
in the program after they meet all the criteria required
by the Ordinance. The drugs used in the treatment and
paid by the State are corticosteroids, salicylates,
antibiotics, immunosuppressant and infliximab, anti–
TNF (tumoral necrosis factor).
We have included in the study patients with IBD that
were enrolled in the high cost pharmacy of  the State of
Mato Grosso, that were above 18 years old, had accepted
to take part in the study, and had their clinical, radiological,
endoscopic and histopathological data assessed. Patients
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with undetermined colitis have been excluded. All
interviews were carried out by one interviewer and 103
patients were randomly chosen from the total of 220
enrolled patients. They were scheduled to answer the three
study questionnaires: the Consensus of Standard-Chart
to collect the sociodemographic variables, disease site and
type of therapy; the “Medical Outcomes Study 36- Item
Short-Form Health Survey” (SF-36)(13) to assess overall
QL, and the “Inflammatory Bowel Disease
Questionnaire” (IBDQ)(14) to assess specific QL related
to the aspects of  IDB.
SF-36 is a multidimensional questionnaire formed
by 36 items, divided into eight domains: physical
functioning, role limitations due to physical health, bodily
pain, general health perceptions, vitality, social functioning,
role limitations due to emotional problems, and mental
health. It presents a final score per domain that can range
from 0 (worst state) to 100 (best state). The IBDQ
questionnaire is formed by 32 items with four domains:
bowel symptoms, systemic symptoms, social and
emotional aspects, and the answer options presented
are multiple-choice with seven alternatives. Score 1 means
the worst state of QL and 7 the best. Both SF-36(15)
and IBDQ(3) have already been translated and validated
in Brazil. To determine the disease activity, we have used
Lichtiger(16) for IUC and the Crohn’s Disease Activity
Index (CDAI)(17), for CD.
Statistical Analysis
To characterize sample data we have carried out
descriptive analysis with values of absolute and
percentage frequencies, medians, means, standard
deviation and standard error for the mean. We have
used a 95% confidence interval to compare the scores
of the domain of the SF-36 of patients with CD and
IUC. The correlation between the variables of the IBDQ
and those from the SF-36 was verified using Pearson’s
coefficient correlation. A multiple regression analysis for
the total IBDQ (dependent variable) was carried out
according to the sociodemographic independent
variables and the domains of  the SF-36. To introduce
the independent variables in the regression model we
used the stepwise process. They were introduced
according to their level of significance, from the smallest
to the highest value. The variables that presented
significant level p<0.05 remained in the regression
model.
RESULTS
Data from table 1 show the sociodemographic and
morbid variables of the 103 IBD patients studied.
In the data from Table 1 we can see that the mean
age of the patients studied was 40.2 years, with
predominance of females (62%), brown (48.5%),
married (69.9%), IUC patients (60.2%) with no need
for surgery because of the disease (62.1%). Mean
schooling was 10 years. At the time of  the study, 42
(40.8%) patients presented active disease. All patients
lived in Mato Grosso, however, 55 (53.4%) were from
the State and the rest 48 (46.6%) were from other places,
with a predominance of the States from the South
(16.5%) and Southeast (12.6%). The age with higher
prevalence of IBD ranged from 20 and 40 years
(48.6%). Of  the 41 patients with CD, the site of  the
disease in 24 (58.5%) was ileal/ileocecal, in 7 (17.1%) it
was ileocolonic, in 5 (12.2%) it was perianal and rectal,
in 4 (9.8%) it was colonic, and 1 (2.4%) it was in the
upper part of the digestive tract. The behavior of CD
in 19 (46.3%) patients was perforating, in 17 (41.5%) it
was non-perforating/non-stenosing and in 5 (12.2%) it
was stenosing. Of  the 62 patients with IUC, 32 (51.6%)
presented proctitis/proctosigmoiditis, 23 (37.1%)
pancolitis; and 7 (11.3%) left-sided colitis. Using the
Truelove & Witts classification(18), 33 (53.2%) patients
presented the mild form of  the disease, 13 (21%) the
moderate form, and 16 (25.8%), the severe form.
Table 1 – Sociodemographic and morbid characteristics
of  patients with IDB. October 2006 to November
2007, Mato Grosso 
Characteristics D II  (n = 103) 
Age (years) 40.2 ± 12.4 
Age variation (years)  18 – 76 
Gender  
Female 64 (62) 
Male 39 (38) 
Skin co lor      
White 45 (43.7) 
Yellow 2 (1.9) 
Black 6 (5.8) 
Brown 50 (48.5) 
Marita l Status      
Married 72 (69.9) 
Single  23 (22.3) 
Divorced 4 (3.9) 
Widow 4 (3.9) 
Smoker  
Yes 51 (49.5) 
No 52 (50.5) 
Diagnoses  
Crohn’s disease 41 (39.8) 
Id iopathic ulcerative colit is 62 (60.2) 
Surgery  
Yes 39 (37.9) 
No 64 (62.1) 
Note: The values are expressed as number (%) or mean ±
standard deviation (SD).
The most commonly used corticosteroid in the
treatment was prednisone, with doses ranging from 2.5
mg to 80 mg (mode 20 mg). All patients used salicylates
and the minimum dose was 0.5g and the maximum dose
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was 6.0g (mode 2.4g). Among immunosuppressants, the
only one used was azathioprine by 24 (23%) patients. Anti
TNF was being used by 14 (13.6%) patients and among
them 10 had the active disease, and four were in remission.
Thirty-nine patients (37.9%) had undergone some sort
of surgical procedure, 27 (26.2%) had diagnosis of CD
and 12 (11.7%), IUC. The scores obtained with the
application of the SF-36 in the 103 patients with CD and
IUC are found in Table 2.
In the data from Table 2, we could observe that the
scores of the SF-36 dimensions of the patients with
CD and IUC were not statistically significant, and that
the values of all dimensions show important involvement
of the quality of life. However, the physical aspect,
vitality and the emotional aspects are the most commonly
affected regardless of the type of disease.  The scores
obtained with the application of the IBDQ in the 103
patients with CD and IUC are found in table 3.
The mean scores resulting from the IBDQ that
assessed specific QL of patients with IBD were not
statistically significant among patients with CD and IBD
in the present study. Data from table 4 show the
Pearson’s correlation coefficient between the domains
of the IBDQ and the SF-36.
When we assessed the coefficients obtained in the
103 patients with IBD, we observed that all domains
of the SF-36 presented medium to high correlation with
the domains of the IBDQ, showing that IBD strongly
affects the quality of life of those who have it, both in
the general and in the specific aspects related to the
disease. Data from Table 5 show multiple linear
regression analysis carried out between the total scores
of IBDQ and those of the SF-36 domains, considering
a p value of £0.05.
Table 2 - Scores of  SF-36 domains of  the 103 patients with IBD. October 2006 to November 2007, Mato
Grosso
Table 3 – Scores of  the Inflammatory Bowel Disease Questionnaire (IBDQ) domains of  patients with IBD.
October 2006 to November 2007, Mato Grosso
Table 4 – Values of  Pearson’s correlation between the SF-36 domains and IBDQ domains of  the 103 patients
with IBD. October 2006 to November 2007, Mato Grosso
 
Mean Score ± standard deviation  
Domain 
*CD (n=41) **IUC (n=62) 
P value 
Physical functioning  64.8 ± 26.3  72.7 ± 25.5  0.13 
Physical role functioning 42.1 ± 41.6  52.8 ± 44.2  0.21 
Bodily Pain 55.2 ± 28.9  50.5 ± 25.4  0.40 
General Health Perception 56.7 ± 21.0  53.4 ± 22.6  0.45 
Vitality 49.9 ± 21.9  54.3 ± 22.7  0.32 
Social role functioning 64.6 ± 27.1  62.5 ± 28.1  0.71 
Emotional role functioning 47.2 ± 38.8  51.6 ± 44.2  0.59 
Mental  Health 55.1 ± 23.4  55.7 ± 21.9  0.89 
*CD (Crohn’s disease); **IUC= idiopathic ulcerative colitis
 
Mean score ± standard deviation 
IBDQ Domains 
CD* (n=41) IUC** (n=62) 
P Value 
Bowel Symptoms 49.3 ± 15.0 47.8 ± 15.0 0.631 
Systemic Symptoms 20.5 ± 7.9 21.3 ± 6.9 0.593 
Social Aspects 23.1 ± 8.4 24.4 ± 8.8 0.441 
Emotional Aspects  54.8 ± 15.1 51.3 ± 15.9 0.263 
*CD (Crohn’s disease); **IUC= idiopathic ulcerative colitis
SF-36 Domains Bowel Symptoms Systemic Symptoms Social Aspects Economic Aspects  
Physical functioning  0.422* 0.601* 0.640* 0.527* 
Physical ro le functioning 0.464* 0.595* 0.664* 0.543* 
Bodily Pain 0.640* 0.696* 0.661* 0.684* 
General Health Perception 0.529* 0.529* 0.528* 0.562* 
Vitality 0.550* 0.655* 0.606* 0.623* 
Social ro le functioning 0.412* 0.608* 0.530* 0.640* 
Emotional ro le functioning 0.379* 0.462* 0.558* 0.505* 
Mental Health 0.431* 0.614* 0.459* 0.731* 
* Statistic significance level lower than or equal to 0.0001 (pd”0.0001).
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Remark: To check the suitability of  the multiple linear
regression model a residual analysis was carried out; after
this analysis, the model was considered adequate. The
constant of this model is 54.4620 (b0=54, 4620) and
the F value calculated is 42.11 (F6,96=42.11) with a
significance level lower than 0.001 (p < 0.001) and
R2=0.72 (total variation of the dependent variable total
IBDQ), which is totalized by the independent variables
of the scores of the SF-36 domains, by
sociodemographic and health related variables.
Table 5 – Multiple linear regression analysis, between
the total score of the Inflammatory Bowel Disease
Questionnaire (IBDQ) and the scores of the SF-36
domains and the sociodemographic variables related to
health of  the 103 patients with IBD, October 2006 to
November 2007, Mato Grosso.
prevalence of the disease among white or brown
individuals, which matched the findings from other
authors(19-20). Data from the present study showed a
predominance of  female IBD, in agreement with other
studies carried out in Brazil(3,20-21). We have also found
QL scores significantly better in women compared to
men. Smokers presented total IBDQ scores lower than
non-smokers. A study shows that smoking is associated
to higher risk for developing IBD(22-23), and it also affects
the QL of those with it(24). Among patients with IUC,
12 (11.7%) needed some type of surgical procedure in
the course of the disease, in patients with CD this amount
corresponded to 27 (26.2%). As for the site of the
disease, among patients with CD, 24 (58.5%) presented
ileal/ileocecal, 4 (9.8%) colonic, 7 (17.1%) ileocolonic,
1 (2.4%) upper digest tract and 5 (12.2%) perianal and
rectal; these findings match other studies(20,25). As for
the extension of the IUC involvement, we have found
the following: 32 (51.6%) patients with proctitis/
proctosigmoiditis, 7 (11.3%) with left-sided colitis and
23 (37.1%) with pancolitis, these findings are compatible
with those found by some authors(20). According to the
Truelove & Witts classification, IUC can be subdivided
into mild (60%-70%), moderate (20%-25%) and severe
(10%-15%); in our casuistic we have obtained: 33
(53.2%) patients with mild, 13 (21%) with moderate
and 16 (25.8%) with severe.
Patients whose disease was active during the study
presented worse both general and specific QL. The high
number of patients with active disease found in the study
(42-40.8%) may be because the high cost pharmacy in
Mato Grosso is a reference center and received both
public and private patients. A study carried out with 50
patients with IBD showed that only 6% of them
presented active disease in the study period(3).
The values of the SF-36 and IBDQ scores found in
patients of the present study were lower than those
found by Brazilian authors(3); however, when the scores
are assessed separately, according to diagnoses, either
CD or IUC, there was no statistically significant
difference. This outcome was similar to that found in a
study carried out in Spain(26).
In the present study, when we analyzed the coefficient
obtained in the 103 patients with IBD, we observed
moderate and high correlations between IBDQ domains
and SF-36 dimensions. The variables that influenced
IBDQ significantly were: male gender, smoking, active
disease, pain, overall health perception, physical aspect
and mental health; however, we could not find previous
studies that reinforced our findings.
In the present study, we observed a high correlation
between emotional aspects of the IBDQ and the
components pain and mental health of the SF-36. A study
found in the literature that focused mental health as a risk
Variable Coefficient EP R2 
Pain  0.6176 0.1238 0.54 
General health perception 0.3622 0.1283 0.06 
Physical aspect 0.1467 0.0700 0.02 
Menta l Health  0.2855 0.1360 0.01 
Disease act ivity 19.1350 4.7450 0.05 
Gender 13.830 4.9540 0.04 
We could observe that both the aspects of  the general
domains of QL, represented by the dimensions of the
SF-36, and the sociodemographic (gender) and morbid
(active disease) variables were responsible for the
worsening of  the specific QL related to the IBD.
Multiple linear regression analysis demonstrated, through
the R2=0.72 (total variation of the dependent variable total
IBDQ), that the variables which affected the most specific
quality of life measured by the total IBDQ were: the SF-
36 domains (mental health 1%, physical role functioning
2% general health perceptions 6%); male gender (4%), active
disease (5%) and pain (54%).
DISCUSSION
IBD can permanently affect the QL of  patients,
especially when it is in a period of exacerbation. The
symptoms presented by IBD patients can lead to
important changes in the attitudes and behaviors, as well
as changes in physical, emotional, and social aspects. The
psychosocial aspects are relevant factors to trigger
outbreaks, although there are not many studies in this
area. Among our subjects we saw a significant amount
of patients that associated the onset of symptoms and
periods of  disease worsening to emotional changes.
In the present study we have found greater
distribution of IBD among the age group from 20 to
40 years old(19), in agreement with the data from the
literature; however, we have not observed another peak
of the disease at the age of 60. There was greater
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factor for IBD did not provide enough data for definite
conclusions(27). A psychological change seems to be a
consequence of the disease and the level of psychological
anguish and disturbances is related to the severity of the
disease and predicts QL, influencing its course(28).
Abdominal pain as an important symptom is more
common when the disease is active, decreasing when it
is inactive, however, this is not an absolute rule because
patients in the different stages can be presented with
different intensity. In the study in which abdominal pain
affected the overall IBDQ score, we observed that this
has been recently reported by other authors(29).
CONCLUSION
Patients presented changes in the QL, especially when
the disease was active, men and smokers presented more
severe outcomes in the QL. Measures to promote and
prevent outbreaks should be introduced as well as the
psychological, social and educational support should be
considered to improve their care and to keep and /or
improve QL of  people with IBD. New studies on the
issue and with other types of design should be carried
out with IBD patients to subsidize health professionals
in their decision on this area.
